NHS advisor says NICE discounts should be public; Hospira, Cubist begin patent fight over antibiotic;

@FiercePharma: Shire reports an enviable 47% spike in Q4 earnings, thanks to ADHD and rare-disease meds. Release | Follow @FiercePharma

> Patient-access discounts that drugmakers offer to the U.K.'s cost-effectiveness agency should be more transparent, a National Health Service advisor said. Story

> Bayer said it expects approval to launch its new stroke drug Xarelto in China within two years. More

> Hospira ($HSP) asked the FDA to approve its version of the Cubist antibiotic Cubicin, and the branded drugmaker said it plans to sue for patent infringement within the required 45 days. Report

> Elan posted a larger net loss for the fourth quarter, but saw its share of sales of the multiple sclerosis drug Tysabri grow to $270.6 million from $229.4 million. Item

> Hungary's Egis saw sales drop during its fiscal third quarter but managed to hike profits by 14% on cost-cutting and currency effects. Article

> The U.S. auditing watchdog group fined Ernst & Young $2 million in a settlement related to Medicis Pharmaceutical's ($MRX) 2005, 2006 and 2007 financial statements. News

> Ireland plans to offer a 30% tax cut for expatriates in a bid to attract more highly skilled jobs in industries such as biopharma. Story

Biotech News

@FierceBiotech: Soligenix' proprietary vaccine thermostabilization technology passed through preclinical proof-of-concept studies. Release | Follow @FierceBiotech

@JohnCFierce: Celgene pays $15M for front-row seat on Acetylon myeloma program. Article | Follow @JohnCFierce

@FierceMedDev: EU wants more medical device controls after PIP scare. News via @Reuters | Follow @FierceMedDev

@MarkHFierce: A U.S. trial will test umbilical cord stem cells to treat /reverse hearing loss in babies. It worked in mice. More | Follow @MarkHFierce

> Cytomedix snaps up stem cell biotech Aldagen for a bargain price. Story

> Celgene pays $15M for front-row seat on Acetylon myeloma program. Article

> GSK's Slaoui opts for more flexible approach in DPU change-up. Report

Manufacturing News

> Pakistan Supreme Court interjects itself in drug death scandal. News

> Being more like Coca-Cola takes days out of GSK's pharma supply chain. More

> Decision on new GSK plant location to come soon. Item

> ViroPharma responding quickly to FDA delay of Cinryze manufacturing expansion. Piece

CRO News

> AZ's China R&D strategy calls for outsourcing. Item

> Takeda opens new drug development center in China. Article

> Quintiles report highlights the challenge of the 'value proposition.' Report

> AstraZeneca's latest restructuring spurs debate over outsourcing R&D. Story

Vaccines News

> Merck's RotaTeq not linked with bowel problems. More

> Novartis' Bexsero successfully protects vast majority of infants. Article

> Researchers target vaccines for the First Nation. Story

> Hints of a heroin vaccine from Mexico. News

> Bacterial cancer vaccines show glimpses of activity. Piece

And Finally... An off-Broadway comedy, "Rx," satirizes pharmaceutical marketing by featuring a pill for people who hate their jobs. Report

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.